Tuesday, February 24, 2009

Eiger BioPharma Gets $7.1M

Palo Alto-based Eiger BioPharmaceuticals Inc. announced Tuesday that its first round of venture financing has yielded $7.1 million. The firm credited InterWest Partners and Vivo Ventures with leading the Series A effort. Both investors helped form Eiger and have general partners on its board of directors, Eiger noted, adding that the money will fund further antiviral research, including ways to target NS4B, a specific location within the hepatitis C virus protein. Eiger also said the capital will be used to help identify other proprietary targets. Eiger is led by Dr. David Cory, the company's president and chief executive officer. More information »